Imatinib mesylate causes hypopigmentation in the skin
نویسندگان
چکیده
منابع مشابه
Imatinib mesylate induced skin hypopigmentation.
Sir, Imatinib mesylate is a tyrosine kinase inhibitor that targets BCR-ABL protein in chronic myelogenous leukemia (CML).1 We present three cases of CML, treated with Imatinib who developed clinical findings of hypopigmentation. All the three patients noticed pigmentation changes after the initiation of therapy with Imatinib mesylate, which was persistent during therapy. The presence of hypopig...
متن کاملImatinib mesylate in polycythemia vera
In the September 15, 2003, issue of Blood,1 Oehler et al describe imatinib mesylate inhibition of the autonomous in vitro proliferation of peripheral blood– and bone marrow–derived polycythemia vera (PV) erythroid burst-forming units (BFU-Es). While their results superficially correlate with the previously published in vivo clinical observations of Silver,2 the conclusions of Oehler et al are a...
متن کاملImatinib mesylate: A designer drug.
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positiv...
متن کاملClinical pharmacokinetics of imatinib mesylate.
This review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
متن کاملPossible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent. The aim of this work was to investigate the possible contribution of interleukin (IL)-33 and IL...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2003
ISSN: 0008-543X,1097-0142
DOI: 10.1002/cncr.11812